37results about How to "Prevention and improvement" patented technology

Disclosed are a combination of active components inducing synergistic effects of multi-targeting and a use thereof. More particularly, disclosed are a functional food composition, a cosmetic composition, a pain-suppressive composition, and a composition for treatment or prevention of pruritus or atopic dermatitis, which comprise as active components, two or more components selected from a group consisting of (a) a 5-hydroxytryptamine subtype 2 (5-HT2) receptor antagonist; (b) a P2X receptor antagonist; and (c) any one of a glycine receptor agonist, a glycine transporter (GlyT) antagonist, a gamma-aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GAT1) antagonist.

The present invention provides a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which contains, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as 3,7-dimethyloctanoic acid ethyl ester, geranic acid ethyl ester, and the like, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-9-decenoic acid methyl ester, and the like, each of which has 10 carbon atoms (C10), trans-10-undecenoic acid methyl ester, trans-10-undecenoic acid ethyl ester, and the like, each of which has 11 carbon atoms (C11), and dodecanoic acid, and the like, each of which has 12 carbon atoms (C12), or salts thereof or prodrugs thereof.

An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1):(In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.

A spherical roller bearing is provided having an outer ring that includes at least one inner raceway, an inner ring that includes a first and a second outer raceway, a plurality of roller elements disposed in a first and second roller row between the at least one inner raceway and the first and second outer raceway, a cage for one of guiding and retaining the roller elements in the first and second roller row, the cage includes a plurality of cage pockets, in which one of the plurality pf rollers is disposed within each cage pocket. The bearing further provides a specific pitch circle diameter (PCD), and when the cage is under-pitch roller centered in relation to the pitch circle diameter (PCD). In addition, a bearing arrangement and a wind turbine bearing arrangement is disclosed.

A spherical roller bearing having an outer ring providing at least one inner raceway, an inner ring providing a first and a second outer raceway, a plurality of roller elements arranged in a first and second roller row in-between the at least one inner raceway and the respective first and second outer raceway is provided. The bearing provides a cage for guiding the roller elements in the first and second roller row, the cage includes a plurality of cage pockets, wherein in each cage pocket one of the roller elements is disposed. The bearing further presents a specific pitch circle diameter (PCD), and the cage is essentially in-pitch roller centered in relation to the pitch circle diameter (PCD) when there is an axial force acting on the bearing. In addition, the present invention regards a bearing arrangement and a wind turbine bearing arrangement.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.